ELTS, Sokal, and Hasford Scores

Ez az eszköz kizárólag oktatási célra szolgál, és nem jelent vagy helyettesít szakmai tanácsot. Az eszköz nem használható orvosi diagnózis felállítására és/vagy orvosi kezelés nyújtására.

General description
The tool calculates prognostic risk group of the EUTOS long-term survival score (ELTS), Sokal and Euro (Hasford) scores for adult patients diagnosed with chronic myeloid leukemia (CML). The score is calculated from patient age, spleen size, blasts in peripheral blood and platelet count. Based on the risk score the patient is assigned to one of the three groups: low-risk, intermediate-risk and high-risk group.

ELTS score =
0.0025 × (age in completed years/10)³
+ 0.0615 × spleen size below costal margin
+ 0.1052 × blasts in peripheral blood
+ 0.4104 × (platelet count/1000)⁻½

Sokal score =
exp ((0.0116 × (age [years] – 43.4))
+ (0.0345 × (spleen size [cm] – 7.51))
+ (0.188 × ((platelets [10⁹/L]/700)² – 0.563))
+ (0.0887 × (blasts % – 2.10)))

Hasford score =
((0.6666 × age [0 when age < 50 years; 1 otherwise])
+ (0.0420 × spleen size [cm])
+ (0.0584 × blasts %)
+ (0.0413 × eosinophils %)
+ (0.2039 × basophils [0 when basophils < 3%; 1 otherwise])
+ (1.0956 × platelet count [0 when platelets < 1500 × 10⁹/L; 1 otherwise])) × 1000

Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789-99.

Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90: 850-8.

Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30;48–56 (2016).

Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28(4):iv41–iv51.